Company: BDRX
Filing Date: 2025-12-11
Form Type: F-1/A
Source: 0001214659-25-017944
Chunk: 10

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-11
Form: F-1/A
Chunk 10
---
 price per share requirement, we effected a
ratio change in the number of Ordinary Shares represented by our Depositary Shares from five Ordinary Shares per Depositary Share to 400
Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued.

On October 4, 2024, and in
an effort to bring our Depositary Share price into compliance with NASDAQ’s minimum bid price per share requirement, we effected
a ratio change in the number of Ordinary Shares represented by our Depositary Shares from 400 Ordinary Shares per Depositary Share to
10,000 Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued.

On November 22, 2024, we held
a general meeting of shareholders, or the November GM, and our shareholders passed resolutions to (i) subdivide our Ordinary Shares of
£0.001 nominal value each into one ordinary share of £0.00005 nominal value and 19 C deferred shares of £0.00005 nominal
value each, each the November Subdivision, and (y) adopt new Articles of Association, which made consequential amendments to the existing
Articles of Association of the Company to reflect the November Subdivision. As is standard for deferred shares, each C deferred share
has very limited rights and is effectively valueless. The C deferred shares have the rights and restrictions as set out in the Articles
of Association and do not entitle the holder thereof to receive notice of or attend and vote at any general meeting of the Company or
to receive a dividend or other distribution.

On June 11, 2025, we held
a general meeting of shareholders, or June 2025 GM, and our shareholders passed resolutions to (i) subdivide our Ordinary Shares of £0.00005
nominal value each into one ordinary share of £0.000001 nominal value and 49 D deferred shares of £0.000001 nominal value
each, each the June 2025 Subdivision, and (y) adopt new Articles of Association, which made consequential amendments to the existing Articles
of Association of the Company to reflect the June Subdivision. As is standard for deferred shares, each D deferred share has very limited
rights and is effectively valueless. The D deferred shares have the rights and restrictions as set out in the Articles of Association
and do not entitle the holder thereof to receive notice of or attend and vote at any general meeting of the Company or to receive a dividend
or other distribution.

| 2